Genia Long

Education

M.P.P., Harvard University; S.B., Massachusetts Institute of Technology 

Summary of Experience

Ms. Long is an expert in the economics and business strategy of innovation and growth. She has assisted executives in pharmaceuticals and biotechnology, consumer packaged goods, and information technology with maximizing the value of their products, services, and innovative technologies by addressing fundamental challenges related to research and development, business planning, opportunity assessment, and competitive market strategy. In health care, Ms. Long’s work has included projects for pharmaceutical and biotech manufacturers; joint ventures in research, teaching, and patient care; academic medical centers; and general and specialty hospitals. For pharmaceutical manufacturers, Ms. Long’s work has encompassed pricing and managed markets strategy, account segmentation, and contracting recommendations for new and established brands; market research studies on branded product demand and launch strategy; pharmacoeconomic analyses of the value and impact of drug therapy; and forecasting and analytical modeling of growth opportunities and business options.

Selected Publishing

• Federal government-interest patent disclosures for recent top-selling drugs

  Journal of Medical Economics, 2019
  2019

  Long G

  HEOR, Epidemiology & Market Access
• Are Payers Ready to Address the Financial Challenges Associated with Gene Therapy?

  Health Affairs, June 28, 2018
  2018

  Ciarametaro M, Long G, Johnson M, Kirson N, Dubois R

  HEOR, Epidemiology & Market Access
• The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development

  Report, July 2017
  2017

  Long G, Llop C

  HEOR, Epidemiology & Market Access
• Challenges in Developing and Assessing Comparative Effectiveness Evidence for Medical Technology

  Decision Making in a World of Comparative Effectiveness Research
  2017

  Price R, Long G

   

  HEOR, Epidemiology & Market Access
• Insurance Switching and Mismatch Between the Costs and Benefits of New Technologies

  The American Journal of Managed Care, December 2017
  2017

  Kirson N, Long G

  HEOR, Epidemiology & Market Access
• Updated trends in US brand-name and generic drug competition

  Journal of Medical Economics, 2016 04: 1-9. e-pub ahead of print 2016/04/12
  2016

  Grabowski H, Long G, Mortimer R, Boyo A.

  HEOR, Epidemiology & Market Access
• Innovation in the Biopharmaceutical Pipeline: A Multidimensional View

  Report, January 2013
  2013

  Long G, Works J

  HEOR, Epidemiology & Market Access, Strategy, Policy & Analytics
• Recent Average Price Trends for Implantable Medical Devices, 2007-2011

  White Paper
  2013

  Long G, Mortimer R, Sanzenbacher G

  HEOR, Epidemiology & Market Access, Strategy, Policy & Analytics
• Recently Released FDA Guidance and Biosimilar Development: Implications for the Litigation Environment

  FDLI Update, March/April 2012
  2012

  Long G, Mulhern C

  HEOR, Epidemiology & Market Access, Intellectual Property
• Data Exclusivity for Biologics

  Nature Reviews Drug Discovery 10, 15-16 (January 2011) - doi:10.1038/nrd3277
  2011

  Long G, Mortimer R, Grabowski H

  HEOR, Epidemiology & Market Access, Intellectual Property, Strategy, Policy & Analytics
• Reading of Biosimilar Law Could Mean One Day or Years Until Competitors on Market

  Specialty Pharmacy News, February 2011, Volume 8, Number 2
  2011

  Long G

  HEOR, Epidemiology & Market Access
• President Reignites Biologics Exclusivity Battle With Proposal for Seven Years

  Specialty Pharmacy News, March 2011, Volume 8, Number 3
  2011

  Long G

  HEOR, Epidemiology & Market Access, Intellectual Property
• Commercial Importation of Prescription Drugs in the United States: Short-Run Implications

  Journal of Health Policy, Politics, and Law, April 2011
  2011

  Danzon P, Johnson S, Long G, Furukawa M

  HEOR, Epidemiology & Market Access, Strategy, Policy & Analytics
• Evolving Brand-Name and Generic Drug Competition May Warrant a Revision of the Hatch-Waxman Act

  Health Affairs, 2011, 30(11), 2157-2166
  2011

  Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N

  HEOR, Epidemiology & Market Access, Intellectual Property, Strategy, Policy & Analytics
• Implementation of the Biosimilar Pathway: Economic and Policy Issues

  Seton Hall Law Review, Book 2, 41:2
  2011

  Grabowski HG, Long G, Mortimer R

  HEOR, Epidemiology & Market Access, Intellectual Property, Strategy, Policy & Analytics
• Budget Proposals on Biosimilars, “Pay for Delay” Spark Controversy

  AIS's Health Reform Week, February 2011, Volume 2, Number 6
  2011

  Long G

  HEOR, Epidemiology & Market Access, Intellectual Property
• Data Exclusivity Periods and Next Generation Improvements to Innovator Biologics: Key Issues

  Duke University Department of Economics Working Paper, No. 2009-05
  2009

  Grabowski H, Cockburn I,  Long G,  Mortimer R

  HEOR, Epidemiology & Market Access
• Data Exclusivity Periods for Biologics: Updating Prior Analyses and Responding to Critiques

  Duke University Department of Economics Working Paper, No. 2008-10
  2008

  Grabowski H, Long G, Mortimer R

  HEOR, Epidemiology & Market Access
• The Value Of Antihypertensive Drugs: A Perspective On Medical Innovation

  Health Affairs
  2007

  Cutler D, Long G, Berndt E, Royer J, Fournier A, Sasser A, Cremieux P

  HEOR, Epidemiology & Market Access, Strategy, Policy & Analytics
• Pharmaceutical Spending and Health Outcomes

  Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective
  2007

  Cremieux P, Jarvinen D, Long G, Merrigan P

  HEOR, Epidemiology & Market Access
• Antihypertensive drugs: a perspective on the value of improved blood pressure control in the USA

  European Heart Journal Supplements
  2007

  Long G, Cutler D, Berndt E

  HEOR, Epidemiology & Market Access
• The Effect on Federal Spending of Legislation Creating a Regulatory Framework for Follow-on Biologics: Key Issues and Assumptions

  White Paper
  2007

  Grabowski H, Cockburn I, Long G, Mortimer R, Johnson S

  HEOR, Epidemiology & Market Access
• The Market For Follow-On Biologics: How Will It Evolve?

  Health Aff 2006 Sep-Oct;25(5):1291-1301
  2006

  Grabowski H, Cockburn I, Long G

  HEOR, Epidemiology & Market Access, Strategy, Policy & Analytics
• The Impact of Antihypertensive Drugs on the Number and Risk of Death, Stroke, and Myocardial Infarction in the United States

  National Bureau of Economic Research Working Paper
  2006

  Berndt E, Sasser A, Long G, Cremieux P, Royer J, Fournier AA

Events

• February 5, 2015

  Senior Advisor Genia Long Presents on Biopharmaceutical Innovation at Health Affairs Event

  Event: Health Affairs Briefing: Biomedical Innovation
  Host: Health Affairs